Calabrese Pasquale, Kobelt Gisela, Berg Jenny, Capsa Daniela, Eriksson Jennifer
Division of Molecular and Cognitive Neuroscience, Department of Psychology, University of Basel, Basel, Switzerland.
European Health Economics, Mulhouse, France.
Mult Scler. 2017 Aug;23(2_suppl):192-203. doi: 10.1177/1352458517708685.
To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated.
This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in CHF 2015.
A total of 721 patients (mean age 48 years) participated in Switzerland; 90% were below retirement age, and of these, 65% were employed. Employment was related to disease severity, and MS affected productivity at work for 69% of patients. Overall, 93% and 64% of patients experienced fatigue and cognition as a problem, respectively. The mean utility and annual costs were 0.799 and 29,600CHF at Expanded Disability Status Scale (EDSS) 0-3, 0.614 and 66,800CHF at EDSS 4-6.5 and 0.348 and 110,800CHF at EDSS 7-9, respectively. The mean cost of a relapse was estimated at 7600CHF.
This study provides current data on MS in Switzerland that are important for development of health policies and to estimate the value of current and future treatments.
为了评估多发性硬化症（MS）干预措施的价值——在无法观察到终身成本和结果的情况下——结果数据必须与成本相结合。这就要求定期更新成本数据。
本研究是一项在16个国家开展的横断面回顾性研究的一部分，收集了MS患者的资源消耗、工作能力、健康相关生活质量（HRQoL）和常见症状的数据。从社会角度，以2015年瑞士法郎为单位，按严重程度水平进行描述性分析。
瑞士共有721名患者（平均年龄48岁）参与；90%未达到退休年龄，其中65%有工作。就业与疾病严重程度相关，MS影响了69%患者的工作生产力。总体而言，分别有93%和64%的患者将疲劳和认知视为问题。在扩展残疾状态量表（EDSS）0 - 3级时，平均效用和年度成本分别为0.799和29,600瑞士法郎；在EDSS 4 - 6.5级时，为0.614和66,800瑞士法郎；在EDSS第7 - 9级时，为0.348和110,800瑞士法郎。一次复发的平均成本估计为7600瑞士法郎。
本研究提供了瑞士MS的当前数据，这些数据对于制定卫生政策以及评估当前和未来治疗的价值具有重要意义。
